Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Significant Drop in Short Interest

Xenetic Biosciences Inc (NASDAQ:XBIO) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 5,500 shares, a decline of 71.6% from the August 15th total of 19,400 shares. Based on an average trading volume of 12,800 shares, the short-interest ratio is presently 0.4 days. Currently, 0.4% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of Xenetic Biosciences in a research note on Tuesday, August 20th.

Xenetic Biosciences Price Performance

NASDAQ:XBIO opened at $3.99 on Friday. The company has a 50 day moving average price of $3.94 and a 200-day moving average price of $4.00. The firm has a market cap of $6.15 million, a price-to-earnings ratio of -1.36 and a beta of 2.24. Xenetic Biosciences has a 1-year low of $2.78 and a 1-year high of $5.97.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.83) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.83). The company had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $0.54 million. Xenetic Biosciences had a negative return on equity of 51.05% and a negative net margin of 186.39%. On average, sell-side analysts anticipate that Xenetic Biosciences will post -1.01 earnings per share for the current fiscal year.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.